LLY

Eli Lilly & Co. Price

Closed
LLY
$1,065.00
+$23.35(+2.24%)

*Data last updated: 2026-05-23 00:03 (UTC+8)

As of 2026-05-23 00:03, Eli Lilly & Co. (LLY) is priced at $1,065.00, with a total market cap of $1.00T, a P/E ratio of 46.76, and a dividend yield of 0.60%. Today, the stock price fluctuated between $1,047.00 and $1,070.25. The current price is 1.71% above the day's low and 0.49% below the day's high, with a trading volume of 2.74M. Over the past 52 weeks, LLY has traded between $623.78 to $1,133.95, and the current price is -6.08% away from the 52-week high.

LLY Key Stats

Yesterday's Close$1,041.65
Market Cap$1.00T
Volume2.74M
P/E Ratio46.76
Dividend Yield (TTM)0.60%
Dividend Amount$1.73
Diluted EPS (TTM)28.25
Net Income (FY)$20.63B
Revenue (FY)$65.17B
Earnings Date2026-08-05
EPS Estimate8.78
Revenue Estimate$20.48B
Shares Outstanding962.85M
Beta (1Y)0.481
Ex-Dividend Date2026-05-15
Dividend Payment Date2026-06-10

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
SectorHealthcare
IndustryDrug Manufacturers - General
CEODavid A. Ricks
HeadquartersIndianapolis,IN,US
Official Websitehttps://www.lilly.com
Employees (FY)50.00K
Average Revenue (1Y)$1.30M
Net Income per Employee$412.76K

Learn More about Eli Lilly & Co. (LLY)

Gate Learn Articles

Is XRP a Good Investment? A Comprehensive Guide to Its PotentialWondering if XRP is a good investment? Discover its pros, risks, market performance, and expert insights to help you decide in 2025.2025-02-25
Exploring Avalon Labs: Building the Future Financial Hub of BitcoinAvalon Labs is actively promoting the financialization of Bitcoin, building a seamless, transparent, and scalable financial ecosystem. Its innovative services, such as Bitcoin-backed lending, stablecoins, yield-generating accounts, and credit cards, aim to make Bitcoin an active economic asset in the global market. This article will detail Avalon Labs' core functions, technical advantages, and market prospects, helping readers to fully understand this project that is reshaping the financial ecosystem.2025-02-12
Beginner's Guide to Contract Trading: From Novice to ExpertWhen novices participate in cryptocurrency contract trading, it is essential to have a deep understanding of the basic knowledge of various contracts, clearly distinguish the characteristics and differences between perpetual contracts and delivery contracts, and make appropriate choices based on their own investment goals and risk preferences. At the trading strategy level, a long-term investment strategy requires precise selection of cryptocurrencies with potential and proficient use of phased opening techniques to reduce costs and risks; short-term trading strategies require clever use of technical indicators, close attention to market hotspots, and seizing fleeting trading opportunities. The most important thing is to pay attention to position management and risk management, so as to achieve stable and long-term profits in the market.2025-01-21

Eli Lilly & Co. (LLY) FAQ

What's the stock price of Eli Lilly & Co. (LLY) today?

x
Eli Lilly & Co. (LLY) is currently trading at $1,065.00, with a 24h change of +2.24%. The 52-week trading range is $623.78–$1,133.95.

What are the 52-week high and low prices for Eli Lilly & Co. (LLY)?

x

What is the price-to-earnings (P/E) ratio of Eli Lilly & Co. (LLY)? What does it indicate?

x

What is the market cap of Eli Lilly & Co. (LLY)?

x

What is the most recent quarterly earnings per share (EPS) for Eli Lilly & Co. (LLY)?

x

Should you buy or sell Eli Lilly & Co. (LLY) now?

x

What factors can affect the stock price of Eli Lilly & Co. (LLY)?

x

How to buy Eli Lilly & Co. (LLY) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Hot Posts About Eli Lilly & Co. (LLY)

MoonlightGamer

MoonlightGamer

05-19 11:02
Lately, I've been pondering an interesting question—why do some people double their investments while others suffer huge losses? The difference lies in choosing the right growth stocks or value stocks. In the past two years, since AI took off, many companies once considered sunset industries suddenly turned into growth stocks, and the U.S. stock indices soared accordingly. Many people around me are chasing stocks like TESLA and NVIDIA; their short-term gains are indeed tempting. But Warren Buffett has been consistently opposing this, insisting that value stocks are the true way to go. Who's right and who's wrong? My understanding is that growth stocks refer to companies still expanding rapidly, with markets not yet saturated, offering unlimited prospects but also carrying unlimited risks. On the other hand, value stocks are about undervalued companies today, focusing on fundamentals and moats. One looks to the future, the other to the present—investment logic is completely different. Take Amazon as an example: in 2000, its P/E ratio exceeded 100, which many thought was crazy. But looking back now, it’s incredibly cheap. A cautionary example is ZOOM: during the pandemic, it gained market share but couldn’t sustain such high valuations, and the bubble eventually burst. So, the key to investing in growth stocks isn’t just buying in but knowing when to exit. When selecting growth stocks, I usually look at a few indicators. First, revenue growth rate should be stable above 20% annually. Second, the industry itself must have growth potential, not a saturated market. Lastly, valuation—long-term high valuation often indicates that big funds are optimistic about the company's prospects, which could be the next breakout point. Regarding growth stock investment opportunities, I’ve noticed that Ark Invest CEO Cathie Wood’s recent focus areas are quite worth considering. She favors Google over NVIDIA in AI because companies providing applications have greater growth potential. In Bitcoin, she sees a huge growth space since global asset allocation to crypto is less than 1%, and Coinbase is also worth watching. Digital finance is very interesting. SOFI is competing with traditional banks, and its projected annual revenue growth rate could stay between 20-25%. In healthcare, LLY has gained popularity due to GLP-1 weight-loss drugs. AI accelerates drug development, helping pharma cut costs, but prices are still rising—this is a long-term beneficiary industry. Everyone knows the story of TESLA: every halving of battery costs results in a 28% price reduction, leading to exponential sales growth. In robotics, ROK, an automation company, has promising prospects, and AI-driven business opportunities are just beginning. 3D printing company PTC integrates hardware and software, and over the next seven years, its market could grow from $18 billion to $180 billion—this is what real growth stock opportunity looks like. But a special reminder: not all companies in growth industries benefit equally. Sometimes, the market fears missing out, and related stocks get hyped up temporarily. Investors need to discern which companies have genuine performance support and which are just riding the trend. Also, even with solid fundamentals, high valuations require caution because a high P/E ratio means the market has already priced in future growth. Growth stocks are indeed volatile, but opportunities and risks coexist. The key is to pick truly growing companies and exit at the right time to lock in profits. If you want to participate in growth stocks, besides stock selection, risk management is crucial. Don’t allocate too much to growth stocks; they should be balanced with value stocks and stable assets. Only then can you build wealth more steadily on the road ahead.
0
0
0
0
Rashid_BNB

Rashid_BNB

05-15 14:51
🚨 Market Update: $750B Wipeout Hits Risk Assets | BTC Under Pressure Below $80K 🚨 Global markets are under heavy selling pressure after a sharp risk-off move erased nearly $750B from U.S. equities within minutes of the open. The panic quickly spilled into crypto, accelerating downside momentum across majors. 📉 Market Snapshot U.S. equities opened deeply red, led by heavy losses in mega caps like AMZN and LLY Semiconductor sector under strong pressure: MU, INTC, QCOM all dropped sharply Crypto followed risk assets lower as liquidity dried up across the board Bitcoin broke below the critical $80,000 support zone ₿ Bitcoin Status Current price: ~$79,134 Intraday pressure: -1.4% Attempting short-term stabilization around $79K–$80K range Liquidation cascade contributed to the breakdown below key support ⚠️ What Triggered the Move? The sell-off was sparked by hot CPI inflation data (3.8%), which reinforced the “higher for longer” Fed narrative. Impact: Rate cut expectations pushed further out Investors rotated into cash / low-risk assets ETF outflows surged to multi-month highs Broad de-risking across equities + crypto simultaneously 📊 Outlook BTC is now in a critical decision zone. Below $80K = bears maintain control Reclaim $80K with volume = possible relief bounce Failure to hold $79K region = risk of deeper liquidity sweep This is not just a crypto dip — it’s a macro-driven risk-off phase hitting all risk assets together. $BTC ‌$AMZNON ‌$LLYON ‌
0
0
0
0